Newsroom
Sorted by: Latest
-
Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-
Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-
Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-
Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-
BostonGene to Present Multimodal AI Advances in Tumor-of-Origin Classification and Tumor Microenvironment Profiling at the ESMO AI & Digital Oncology Congress 2026
WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of an AI model for tumor and immune biology, today announced its participation in ESMO AI & Digital Oncology Congress 2026 taking place November 16–18, 2026 in Berlin, Germany. The international forum unites oncologists, data scientists, and industry leaders to showcase advances in AI and computational biology across cancer care. BostonGene will demonstrate how its multimodal AI platform addresses critical oncology challenges, including...
-
Next 15 Group plc UK Regulatory Announcement: Admission to Trading
LONDON--(BUSINESS WIRE)-- 16 November 2026 Next 15 Group plc (“Next 15” or the “Company”) Additional Listing Next 15 Group plc announces that application has been made to the London Stock Exchange for 176,336 new ordinary shares of 2.5 pence each in the Company (‘Ordinary Shares’) to be admitted to AIM. An application has been made in respect of the Ordinary Shares to be issued as consideration in connection with the vesting of long-term incentives in relation to M. Booth & Associates LLC....
-
TRIMTECH Therapeutics Enters Strategic Research Collaboration With Biogen to Advance Small Molecule Degraders for Neurodegenerative Disease
CAMBRIDGE, England--(BUSINESS WIRE)--TRIMTECH Therapeutics, a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, today announced it has entered into a strategic research collaboration, option, and license agreement with Biogen International GmbH. Under the terms of the agreement, Biogen and TRIMTECH will work collaboratively to discover and develop small molecule protein degraders for the treatme...
-
Des résultats de coopération de grande valeur : L'événement « Visite des entreprises eurasiennes à Chongqing » affiche un bilan d'ouverture en hausse quantitative et qualitative
CHONGQING, Chine--(BUSINESS WIRE)--Visite des entreprises eurasiennes à Chongqing » s'est tenu dans la municipalité de Chongqing. Placé sous le thème « Chongqing : Bâtir de nouveaux ponts avec l'Eurasie », cet événement a mis en place un système d'activités tridimensionnel articulé autour de « 1 conférence sur les partenariats industriels+ 16 rencontres ciblées + 9 visites industrielles dans les districts et comtés + 4 expositions de résultats ». Des négociations et des rencontres ont été menée...
-
High-Value Deals, Growing Global Reach: Chongqing Visit by Eurasian Enterprises Delivers in Both Scale and Substance
CHONGQING, China--(BUSINESS WIRE)--The Chongqing Visit by Eurasian Enterprises took place on November 12–13 under the theme “Chongqing: Forging New Connections Across Eurasia.” The event featured one industry matchmaking conference, 16 targeted matchmaking sessions, nine industrial site visits across Chongqing’s districts and counties, and four showcases of cooperation outcomes. Focusing on key sectors such as intelligent connected new energy vehicles, advanced materials, smart equipment, and b...
-
Seawolf Therapeutics Debuts With $100 Million to Advance DNA-Based Therapeutics
SAN DIEGO--(BUSINESS WIRE)--Seawolf Therapeutics (“Seawolf”) today announced its emergence from stealth, having raised $100 million to transform patient outcomes through the use of its proprietary DNA delivery platform. Founding investor Versant Ventures led the seed round, followed by the Series A financing with Versant, MPM BioImpact, and Novartis Venture Fund (NVF), and participation from Eli Lilly and Company, CRISPR Therapeutics AG, Sixty Degree Capital, Alexandria Venture Investments, Pat...